Form D · Biotechnology
Lexaria Bioscience Corp.
Kelowna, A1 · CIK 0001348362
Offering snapshot reported Sep 21, 2026 · SEC filing
- Reported sold
- $113K Offering amount: $113K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2026 | Initial | $113,492 | No comparison | 3 | SEC filing |
| Dec 19, 2025 | Initial | $3,500,004 | No comparison | 5 | SEC filing |
| Oct 1, 2025 | Initial | $4,000,000 | No comparison | 5 | SEC filing |
| Oct 16, 2024 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| May 2, 2024 | Initial | $364,629 | No comparison | 1 | SEC filing |
| Feb 16, 2024 | Initial | $3,600,003 | No comparison | 2 | SEC filing |
| Oct 4, 2023 | Initial | $1,569,780 | No comparison | 1 | SEC filing |
| Dec 20, 2021 | Initial | $1,200,000 | No comparison | 1 | SEC filing |
| Jul 27, 2021 | Initial | $85,000 | No comparison | Not reported | SEC filing |
| Jul 8, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
| May 13, 2020 | Initial | $2,039,228 | No comparison | 21 | SEC filing |
| Nov 19, 2019 | Initial | $492,500 | No comparison | 5 | SEC filing |
| Nov 13, 2019 | Initial | $180,000 | No comparison | 1 | SEC filing |
| Nov 15, 2018 | Initial | $310,000 | No comparison | 3 | SEC filing |
| Sep 13, 2016 | Initial | $108,500 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $7.94K
- Finders' fees
- $0
- Form D file number
- 021-598175
Value represents proceeds received from warrants issued. The warrants were issued pursuant to a warrant inducement agreement whereby warrant holders agreed to exercise their warrants at market price and were issued 2x replenishment warrants
Represents 7% of monies received for the warrants issued. Placement agent also received an additional $402,625.10 being 7% of the proceeds received from the exercise of warrants under the warrant inducement agreement
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. WAINWRIGHT & CO. | 375 |
Source: Form D, filed Sep 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicholas Baxter | Director |
| Bal Bhullar | Director |
| Christopher Bunka | Director |
| Chris Bunka | Director, Executive |
| Nelson Cabatuan | Executive |
| Richard Christopher | Director, Executive |
| John Docherty | Director, Executive |
| Gregory Downey | Executive |
| Ted Mckechnie | Director |
| William Edward Mc Kechnie | Director |
| Ted Mc Kechnie | Director |
| Brian Quigley | Director |
| Albert Reese | Director |
| Michael Shankman | Executive |
| Allan Spissinger | Executive |
| Catherine Turkel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 740 Mccurdy Road
Kelowna, A1, V1X 2P7
Phone: 250-765-6424
Kelowna, A1, V1X 2P7
Phone: 250-765-6424